In a KRAS-mutant lung cancer model, the inhibition of CCL5 and interleukin (IL)-6 could hamper cancer growth, suggesting that KRAS mutation may be involved in tumor progression via the production of cytokines 150. This evidence concerns the gene KRAS and lung carcinoma.